Making a Cone Snail Venom Peptide More Stable and More Potent by Connecting Its Ends Into a Loop

Backbone cyclization of α-conotoxin CIA produced analogues that retained low nanomolar potency at muscle-type nicotinic receptors while gaining up to 52-fold higher potency at the neuronal α3β2 subtype (IC50 1.3 nM). The cyclic analogues also showed greatly improved resistance to degradation in human serum. When tested in zebrafish, the peptides were highly paralytic both by injection (adults) and bath application (larvae), demonstrating barrier-crossing ability and efficient uptake — unusual properties for peptides of this size.

Researchers designed cyclic analogues of α-conotoxin CIA using backbone cyclization. They tested the analogues' potency against muscle-type and neuronal (α3β2) nicotinic acetylcholine receptors, measured their stability in human serum, determined their 3D structures using NMR spectroscopy, and assessed their biological activity in vivo using zebrafish injection and bath application models.

Venom peptides are a rich source of potential drugs, but their clinical use is typically limited by rapid breakdown in the body and poor absorption. This study shows that a simple chemical modification — connecting the peptide's backbone into a loop — can simultaneously solve stability problems and unexpectedly enhance potency at a key receptor subtype. This approach could be broadly applied to other venom-derived peptide drug candidates.

Venom-derived peptides represent a vast library of naturally evolved drug-like molecules — there are already approved drugs based on cone snail toxins (e.g., ziconotide for pain). This study demonstrates that backbone cyclization can simultaneously improve two of the biggest barriers to peptide drug development: metabolic stability and receptor potency. The unexpected gain in neuronal receptor activity also suggests that cyclization may reveal hidden pharmacological profiles in venom peptides, opening new therapeutic possibilities.

The in vivo testing was limited to zebrafish models, which, while useful for demonstrating bioactivity and barrier crossing, do not directly predict mammalian pharmacokinetics or therapeutic potential. No mammalian in vivo studies were reported. The structural explanations for the gain in α3β2 potency are based on NMR comparison and remain speculative without co-crystal structures with the receptor.